Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

telotristat × NET × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1 Endocrine 1

Conditions

Neuroendocrine Tumors 1

Interventions

lutetium Lu 177 dotatate 46 Everolimus 35 Magnetic Resonance Spectroscopy 20 Temozolomide 15 lanreotide 14 Octreotide 14 gallium Ga 68 dotatate 13 Capecitabine 12 Nivolumab 11 177Lu-octreotide, DOTA(0)-Tyr(3)- 11 surufatinib 10 cabozantinib 10 pembrolizumab 9 Sunitinib 9 Specimen Handling 9 pasireotide 8 Positron Emission Tomography Computed Tomography 8 3-Iodobenzylguanidine 8 Lutetium-177 7 Ga(III)-DOTATOC 7 amino-acid, glucose, and electrolyte solution 6 Somatostatin 6 Fluorodeoxyglucose F18 6 Carboplatin 6 90Y-octreotide, DOTA-Tyr(3)- 6 telotristat ethyl 5 copper dotatate CU-64 5 Ipilimumab 5 Injections 5 Etoposide 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04543955 2023-06-27

Telotristat With Lutathera in Neuroendocrine Tumors

University of Kentucky

Phase 2 Terminated

1 enrolled 4 charts

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡